XML 56 R46.htm IDEA: XBRL DOCUMENT
v3.23.2

In-Licensing and Supply - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jun. 30, 2018 | Jun. 30, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2019
Aegis Therapeutics Agreement |  |  |  |  |  |  |
Defined Benefit Plan Disclosure [Line Items] |  |  |  |  |  |  |
Upfront License Fees | $ 50,000,000 |  |  |  |  |  |
Aggregate milestone payments upon achievement of certain sales milestones |  |  |  |  | $ 20,000,000.0 |  |
Notice Period Description |  |  |  |  | The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement. |  |
Legal Patent Fees |  |  |  |  | $ 0 | $ 0 |
Supply Agreement Expense |  | $ 300,000 |  | $ 0 | $ 200,000 | $ 0 |
Aegis Therapeutics Agreement | New Drug Application |  |  |  |  |  |  |
Defined Benefit Plan Disclosure [Line Items] |  |  |  |  |  |  |
Aggregate Milestone Payments |  |  | $ 1,000,000.0 |  |  |  | $ 500,000
Renaissance Agreement |  |  |  |  |  |  |
Defined Benefit Plan Disclosure [Line Items] |  |  |  |  |  |  |
Contract Termination Claims, Description |  |  |  |  | Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the Company has not submitted a regulatory filing for any Renaissance Product in the U.S. on or before June 30, 2022, (b) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before the target U.S. launch date, (c) the authorization and approval representing more than a targeted number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (d) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws. |  |

X
- Definition Aggregate Milestone Payments + References No definition available. + Details
Name: | spry_AggregateMilestonePayments
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate milestone payments upon achievement of certain sales milestones. + References No definition available. + Details
Name: | spry_AggregateMilestonePaymentsUponAchievementOfCertainSalesMilestones
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Legal Patent Fees + References No definition available. + Details
Name: | spry_LegalPatentFees
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Notice Period Description + References No definition available. + Details
Name: | spry_NoticePeriodDescription
Namespace Prefix: | spry_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Supply Agreement Expense + References No definition available. + Details
Name: | spry_SupplyAgreementExpense
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront License Fees + References No definition available. + Details
Name: | spry_UpfrontLicenseFees
Namespace Prefix: | spry_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=84167097&loc=d3e55541-109407 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=84167097&loc=d3e55538-109407 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 275 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126938061&loc=d3e54672-109401 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 405 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126938335&loc=d3e56414-109416 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 275 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126938061&loc=d3e54708-109401 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 405 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126938335&loc=d3e56417-109416 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 275 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126938061&loc=d3e54658-109401 + Details
Name: | us-gaap_ContractTerminationClaimsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DefinedBenefitPlanDisclosureLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_AegisTherapeuticsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=spry_NewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=spry_RenaissanceLakewoodLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |